Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

I put Gemini 3.0 and Grok 4.1 through 9 head-to-head prompts — from logic and creativity to humor and tone. Here's what ...

A deep learning framework enhances medical image recognition by optimizing RNN architectures with LSTM, GRU, multimodal fusion, and CNN integration. It improves dynamic lesion detection, temporal ...

Burmese pythons, a non-native snake, has proliferated across more than a thousand square miles of South Florida.